Author(s): K Swaminathan, HCS Howlett, IW CampbellJournal Issue: Volume 39: Issue 1: 2009 Format Abstract An ever-increasing number of women with Type 2 diabetes mellitus (DM) are going through pregnancy and, with the current epidemic of obesity, more women are being diagnosed with gestational diabetes mellitus (GDM). Insulin has traditionally been the gold standard in diabetic pregnancy because of its efficacy and the fact that it does not cross the placenta. However, recent data from well-designed trials and meta-analysis on the use of oral agents in gestational diabetes may mark a significant shift in clinical practice. Evidence for metformin use in GDM has been enhanced by the MiG trial, but a randomised controlled trial in women with Type 2 DM in pregnancy is required. No long-term follow-up data for offspring of mothers receiving metformin have been published, apart from reassuring findings in one study with an 18-month follow-up period. The aim of this article is to review the safety, efficacy and future of metformin in diabetic pregnancy. PDF https://www.rcpe.ac.uk/sites/default/files/campbell_1.pdf